Detail akcie CHUGAI PHARM online

Business Summary: CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Chugai Pharmaceutical Co Ltd revenues decreased 5% to Y552.86B. Net income applicable to common stockholders increased 19% to Y186.26B. Revenues reflect Japan segment decrease of 31% to Y218.1B, Other foreign segment decrease of 21% to Y15.89B. Net income reflects Impairment of Intangibles - R&D decrease of 98% to Y88M (expense), Selling, general and administrative expe decrease of 8% to Y49.9B (expense).